{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:59:50Z","timestamp":1787795990802,"version":"build-2784847793"},"reference-count":39,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Glioblastoma (GBM) remains the most aggressive primary malignant brain tumor in adults, with limited survival benefit from the current standard of care consisting of maximal safe resection, radiotherapy, and temozolomide-based chemotherapy. The highly infiltrative growth pattern, profound intratumoral heterogeneity, and strongly immunosuppressive tumor microenvironment together contribute to therapeutic resistance and frequent recurrence. In this context, oncolytic herpes simplex virus (oHSV) has emerged as a promising therapeutic platform for glioblastoma because of its dual capacity to directly lyse tumor cells and stimulate antitumor immune responses. In addition, the large viral genome and well-characterized biology of herpes simplex virus enable extensive genetic engineering to improve tumor selectivity, safety, and immunomodulatory function. In this review, we summarize the molecular design strategies that have driven the development of oHSV for glioblastoma, including attenuation of neurovirulence, enhancement of tumor-selective replication, and arming with immune-stimulatory transgenes. We further discuss the major biological barriers within the GBM tumor microenvironment that continue to limit therapeutic efficacy, with particular attention given to representative engineered oHSV platforms and the lessons learned from preclinical and early-phase clinical studies. A dedicated section examines these barriers in detail, including restricted intratumoral viral spread, antiviral innate immunity, and immunosuppressive myeloid cell dominance. We also review current efforts to improve outcomes through rational combination strategies with radiotherapy, immune checkpoint blockade, cytokine modulation, and other multimodal approaches. Although encouraging advances have been achieved, the clinical translation of oHSV therapy for glioblastoma still faces substantial challenges in patient selection, delivery optimization, response assessment, and treatment integration. A deeper understanding of virus\u2013host\u2013tumor interactions and more precise engineering of viral platforms may help unlock the full potential of oHSV-based therapy. Overall, oHSV represents one of the most compelling translational approaches in glioblastoma and provides a valuable framework for the development of mechanism-driven viro-immunotherapy in neuro-oncology.<\/jats:p>","DOI":"10.3390\/cimb48050499","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T08:55:28Z","timestamp":1779180928000},"page":"499","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oncolytic\u00a0Herpes Simplex Virus for Glioblastoma: Molecular Engineering, Tumor Microenvironment Barriers, and Clinical Translation"],"prefix":"10.3390","volume":"48","author":[{"given":"Jiayu","family":"Liu","sequence":"first","affiliation":[{"name":"Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Wang","sequence":"additional","affiliation":[{"name":"Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Gao","sequence":"additional","affiliation":[{"name":"Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtan","family":"Liu","sequence":"additional","affiliation":[{"name":"The Brain Cognition and Brain Disease Institute, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Xu","sequence":"additional","affiliation":[{"name":"Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxuan","family":"Li","sequence":"additional","affiliation":[{"name":"Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[{"name":"Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Song","sequence":"additional","affiliation":[{"name":"Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-030X","authenticated-orcid":false,"given":"Baorui","family":"Guo","sequence":"additional","affiliation":[{"name":"Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2388-6062","authenticated-orcid":false,"given":"Huadong","family":"Wang","sequence":"additional","affiliation":[{"name":"The Brain Cognition and Brain Disease Institute, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Lv","sequence":"additional","affiliation":[{"name":"Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianning","family":"Zhang","sequence":"additional","affiliation":[{"name":"Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2478\/raon-2018-0023","article-title":"Radiotherapy of Glioblastoma 15 Years after the Landmark Stupp\u2019s Trial: More Controversies than Standards?","volume":"52","author":"Kazda","year":"2018","journal-title":"Radiol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"De Vleeschouwer, S. (2017). Current Standards of Care in Glioblastoma Therapy. Glioblastoma, Codon Publications.","DOI":"10.15586\/codon.glioblastoma.2017"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1186\/s12967-024-05301-9","article-title":"The tumour microenvironment, treatment resistance and recurrence in glioblastoma","volume":"22","author":"White","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Liu, J., Wang, Y., Su, S., Cheng, G., Zhao, H., Sun, J., Sun, G., Li, F., Hui, R., and Liu, M. (2025). Oncolytic Viruses in Glioblastoma: Clinical Progress, Mechanistic Insights, and Future Therapeutic Directions. Cancers, 17.","DOI":"10.3390\/cancers17243948"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"217185","DOI":"10.1016\/j.canlet.2024.217185","article-title":"Suppressive immune microenvironment and CART therapy for glioblastoma: Future prospects and challenges","volume":"600","author":"Lu","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kardani, K., Sanchez Gil, J., and Rabkin, S.D. (2023). Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells. Front. Cell Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1206111"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ning, J., and Wakimoto, H. (2014). Oncolytic herpes simplex virus-based strategies: Toward a breakthrough in glioblastoma therapy. Front. Microbiol., 5.","DOI":"10.3389\/fmicb.2014.00303"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bernstock, J.D., Hoffman, S.E., Chen, J.A., Gupta, S., Kappel, A.D., Smith, T.R., and Chiocca, E.A. (2021). The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies. Viruses, 13.","DOI":"10.3390\/v13061158"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Aldrak, N., Alsaab, S., Algethami, A., Bhere, D., Wakimoto, H., Shah, K., Alomary, M.N., and Zaidan, N. (2021). Oncolytic Herpes Simplex Virus-Based Therapies for Cancer. Cells, 10.","DOI":"10.3390\/cells10061541"},{"key":"ref_11","first-page":"103","article-title":"Herpesvirus vectors for therapy of brain tumors","volume":"4","author":"Cassady","year":"2010","journal-title":"Open Virol. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.apsb.2026.01.015","article-title":"Targeting immunosuppressive network in glioblastoma: Emerging strategies to overcome immunodeficiency and enhance therapeutic efficacy","volume":"16","author":"Zhou","year":"2026","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.gt.3301205","article-title":"Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial","volume":"7","author":"Markert","year":"2000","journal-title":"Gene Ther."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Alomari, O., Eyvazova, H., G\u00fcney, B., Al Juhmani, R., Odabasi, H., Al-Rawabdeh, L., Mokresh, M.E., Erginoglu, U., Keles, A., and Baskaya, M.K. (2025). Oncolytic Therapies for Glioblastoma: Advances, Challenges, and Future Perspectives. Cancers, 17.","DOI":"10.3390\/cancers17152550"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/mt.2008.228","article-title":"Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM","volume":"17","author":"Markert","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/mt.2014.22","article-title":"A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses","volume":"22","author":"Markert","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/humc.2016.031","article-title":"Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent\/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma","volume":"27","author":"Patel","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1089\/humc.2013.201","article-title":"Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates","volume":"25","author":"Roth","year":"2014","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1586\/ern.09.9","article-title":"Design and application of oncolytic HSV vectors for glioblastoma therapy","volume":"9","author":"Grandi","year":"2009","journal-title":"Expert. Rev. Neurother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"ltaf024","DOI":"10.1093\/immadv\/ltaf024","article-title":"Going viral: Targeting glioblastoma using oncolytic viruses","volume":"5","author":"Coates","year":"2025","journal-title":"Immunother. Adv."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Zheng, Y., Pei, Y., Dong, C., Liang, J., Cai, T., Zhang, Y., Tan, D., Wang, J., and He, Q. (2025). Oncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook. Vaccines, 13.","DOI":"10.3390\/vaccines13080880"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1126\/science.2173860","article-title":"Mapping of Herpes Simplex Virus-1 Neurovirulence to \u03b3134.5, a Gene Nonessential for Growth in Culture","volume":"250","author":"Chou","year":"1990","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm0995-938","article-title":"Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas","volume":"1","author":"Mineta","year":"1995","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1128\/JVI.73.8.6319-6326.1999","article-title":"Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates","volume":"73","author":"Hunter","year":"1999","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2017.02.001","article-title":"Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates","volume":"5","author":"Cassady","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"115547","DOI":"10.1016\/j.intimp.2025.115547","article-title":"Oncolytic virus therapy for glioma: Current clinical trials and overcoming key obstacles","volume":"166","author":"Zhang","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1158\/1078-0432.CCR-14-3118","article-title":"The Impact of Macrophage- and Microglia-Secreted TNF\u03b1 on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment","volume":"21","author":"Meisen","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6167","DOI":"10.2147\/JMDH.S557248","article-title":"Oncolytic Virotherapy for Glioma: A Bibliometric Roadmap for Multidisciplinary Clinical and Research Strategies","volume":"18","author":"Liu","year":"2025","journal-title":"J. Multidiscip. Healthc."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Suryawanshi, Y.R., and Schulze, A.J. (2021). Oncolytic Viruses for Malignant Glioma: On the Verge of Success?. Viruses, 13.","DOI":"10.20944\/preprints202105.0007.v1"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"123595","DOI":"10.1016\/j.wneu.2024.123595","article-title":"Herpes Simplex Oncolytic Viral Therapy for Malignant Glioma and Mechanisms of Delivery","volume":"194","author":"Erickson","year":"2025","journal-title":"World Neurosurg."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Qian, Z., Gao, Q., and Zhang, W. (2026). Combination of oncolytic viruses and immune checkpoint inhibitors for treatment of high-grade gliomas. Front. Neurol., 17.","DOI":"10.3389\/fneur.2026.1683726"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: A phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s40259-022-00553-7","article-title":"Teserpaturev\/G47\u0394: First Approval","volume":"36","author":"Frampton","year":"2022","journal-title":"BioDrugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/oncolo\/oyad041","article-title":"Regulatory Issues: PMDA\u2014Review of Sakigake Designation Products: Oncolytic Virus Therapy with Delytact Injection (Teserpaturev) for Malignant Glioma","volume":"28","author":"Maruyama","year":"2023","journal-title":"Oncologist"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OV.S268426","article-title":"The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment","volume":"10","author":"Nguyen","year":"2021","journal-title":"Oncolytic Virother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1097\/MS9.0000000000002384","article-title":"Synergistic effects of herpes oncolytic virus and cyclophosphamide for recurrent malignant glioma: A narrative review","volume":"86","author":"Iqbal","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Chambers, M.R., Bentley, R.T., Crossman, D.K., Foote, J.B., Koehler, J.W., Markert, J.M., Omar, N.B., Platt, S.R., Self, D.M., and Shores, A. (2020). The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination with a Checkpoint Inhibitor in Canine Patients with Sporadic High Grade Gliomas. Front. Surg., 7.","DOI":"10.3389\/fsurg.2020.00059"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2217\/imt-2018-0009","article-title":"Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma","volume":"10","author":"Saha","year":"2018","journal-title":"Immunotherapy"}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/5\/499\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:37:35Z","timestamp":1779183455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/5\/499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cimb48050499"],"URL":"https:\/\/doi.org\/10.3390\/cimb48050499","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]}}}